ShineOn’s exclusive technology addresses protein precipitation caused by unexpected folding in a structure composed of multi-specific antibodies, offering a great flexibility in multi-specific antibody design for enhanced targeting efficacy. This advancement reduces the effective dosage required compared to mono-specific and bispecific antibodies, thereby improving drug safety.
Two pipeline antibody products have been developed referring to SOA101 and SOA201.
![](/upload/images/%E4%B8%89%E7%89%B9%E7%95%B0%E6%80%A7T%E7%B4%B0%E8%83%9E%E6%8A%97%E9%AB%94.jpg)